Milciclib - CAS 802539-81-7
Catalog number: B0084-459709
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C25H32N8O
Molecular Weight:
460.57
COA:
Inquire
Targets:
CDK
Description:
Milciclib is an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some cancer cell types. The neurotrophin receptor TRKA is mutated in a variety of cancer cell types.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-459709 5 mg $188 In stock
B0084-459709 10 mg $348 In stock
Bulk Inquiry
Purity:
>98%
Appearance:
Light yellow to yellow solid
Synonyms:
PHA-848125; PHA848125; PHA 848125; PHA-848125AC; PHA 848125AC; PHA848125AC
MSDS:
Inquire
InChIKey:
RXZMYLDMFYNEIM-UHFFFAOYSA-N
InChI:
InChI=1S/C25H32N8O/c1-25(2)14-16-15-27-24(29-20(16)22-19(25)21(23(34)26-3)30-32(22)5)28-17-6-8-18(9-7-17)33-12-10-31(4)11-13-33/h6-9,15H,10-14H2,1-5H3,(H,26,34)(H,27,28,29)
Canonical SMILES:
CC1(CC2=CN=C(N=C2C3=C1C(=NN3C)C(=O)NC)NC4=CC=C(C=C4)N5CCN(CC5)C)C
Current Developer:
Nerviano Medical Sciences.
1.Epidemiological Surveillance of Leishmaniasis in Montenegro, 1992-2013.
Medenica S, Jovanović S, Dožić I, Milicić B, Lakićević N, Rakocević B. Srp Arh Celok Lek. 2015 Nov-Dec;143(11-12):707-11.
INTRODUCTION: The diseases caused by Leishmania are spread worldwide and represent a significant public health problem.
2.INTRAOPERATIVE ANEURYSMAL RUPTURE: CLINICAL OUTCOME FOLLOWING OPEN SURGERY OR ENDOVASCULAR TREATMENT.
Lakićević N, Prstojević B, Rasulić L, Vujotić L, Vukašinović Ivan, Miličić B, Savić A, Živković B, Rotim K, Samardžić M. Acta Clin Croat. 2015 Sep;54(3):285-94.
The aim of this study was to evaluate and compare the outcomes of intraoperative aneurysmal rupture in patients with subarachnoid hemorrhage undergoing open surgical or endovascular treatment. This retrospective study included 742 patients with aneurysmal subarachnoid hemorrhage treated at the Clinical Department of Neurosurgery, Clinical Center of Serbia, during a three-year period. Among them, 167 (31.15%) were treated by clipping and 33 (16.01%) by coiling in the early phase (≤72 hours). The overall outcome and pretreatment variables were analyzed for each group, including between-group difference according to the occurrence of intraoperative aneurysmal rupture. Intraoperative aneurysmal rupture occurred in 14.7% of microsurgical and 2.4% of endovascular procedures. It was more frequent in early procedures as compared with delayed procedures (27.5% and 9.7% vs. 2.2% and 1.1%, respectively). On the contrary, mortality rates were lower in the surgical group (11.
3.Analysis of cervical resistance during continuous controllable balloon dilatation: controlled clinical and experimental study.
Arsenijevic P1, Milosevic M2, Zivanovic A3, Milicic B4, Jeremic B5, Filipovic N6, Protrka Z7, Todorovic P8, Arsenijevic S9. Trials. 2015 Oct 28;16:485. doi: 10.1186/s13063-015-1003-8.
BACKGROUND: Hydraulic dilatation is a novel method of cervical dilatation that is based on continuous controllable dilatation (CCBD) by the pumping of fluid into the balloon extension of the system. The main advantage of this procedure is that it allows control of and insight into the process of cervical dilatation.
4.Impact of the lower third molar and injury mechanism on the risk of mandibular angle and condylar fractures.
Antic S1,2, Milicic B3,4, Jelovac DB5, Djuric M2. Dent Traumatol. 2016 Jan 28. doi: 10.1111/edt.12259. [Epub ahead of print]
BACKGROUND: Previous studies have shown the influence of the mandibular third molar on mandibular angle and condylar fractures, but have not comparatively analyzed the impact of the injury mechanism on these fractures. The purpose of this study was to evaluate the influence of the lower third molar (M3) and injury-related factors (fracture etiology and site of impact of the traumatic force) on the risk of mandibular angle and condylar fractures.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CDK Products


CAS 827022-32-2 Palbociclib HCl

Palbociclib HCl
(CAS: 827022-32-2)

Palbociclib, also known as PD0332991, is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic acti...

CAS 784210-87-3 RGB-286638

RGB-286638
(CAS: 784210-87-3)

RGB-286638 is a novel CDK inhibitor. It inhibited several tyrosine and serine/threonine non-CDK enzymes, i.e. GSK-3β, TAK1, AMPK, Jak2, MEK1. It demonstrated eq...

CAS 1431697-85-6 AT7519 trifluoroacetate

AT7519 trifluoroacetate
(CAS: 1431697-85-6)

AT7519 is an ATP competitive CDK inhibitor with a Ki value of 38 nM for CDK1. AT7519 is inactive against all non-CDK kinases with the exception of GSK3β (IC50 =...

CAS 1421693-22-2 CDKI-73

CDKI-73
(CAS: 1421693-22-2)

CDKI-73 was cytotoxic to all of the CLL samples tested (n = 38) with a mean LD50 value of 0.08μM ± 0.10 μM following exposure to drug for 48h. In contrast, norm...

CAS 827022-33-3 Palbociclib Isethionate

Palbociclib Isethionate
(CAS: 827022-33-3)

Palbociclib is a potent Cdk4/6 inhibitor.

CAS 496864-16-5 Aloisine A

Aloisine A
(CAS: 496864-16-5)

Aloisine a is a cell-permeable pyrrolo-pyrazine compound that acts as a potent, selective, reversible, and ATP-competitive inhibitor of cyclin dependent kinases...

CAS 1604810-83-4 THZ1

THZ1
(CAS: 1604810-83-4)

THZ1 is a selective CDK7 inhibitor that preferentially diminishes transcription in cancer cells. THZ1 has the unprecedented ability to target a remote cysteine ...

CAS 1231929-97-7 Abemaciclib

Abemaciclib
(CAS: 1231929-97-7)

Abemaciclib is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with poten...

Chemical Structure

CAS 802539-81-7 Milciclib

Quick Inquiry

Verification code

Featured Items